Verisante Technology, Inc.

Verisante Technology, Inc.

March 20, 2013 12:57 ET

Verisante Announces Official Launch of Aura in Germany

Exclusive Distributor, Laserwelt, Exhibits the Revolutionary Skin Cancer Detector at Major Dermatology Conference in Frankenthal, Germany

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 20, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced that Laserwelt, the Company's exclusive distributor for Aura™ in Germany, Austria and Liechtenstein held an official product launch at the Annual Dermatology Congress "Dermatologic Practice" in cooperation with the German association of dermatologists, the German society of dermatologic surgery, the European society of laser dermatology and the Luxemburg society of dermatology in Frankenthal, Germany from March 15-17, 2013.

The German association of dermatologists has nearly 3,400 members, including over 90% of German dermatologists, who are mainly in private practice. Their Annual Dermatology Conference is organized by Prof. Dr. Klaus Fritz, President of the German Academy of Dermatology, Past President of the European Society of Laser Dermatology and Secretary General of the German Dermatologist Association. Dr. Fritz, who leads a private dermatology practice of three clinics and five dermatologists in Germany, also made a presentation about Aura™ at the conference, conducting the first live demonstration of Aura™ in Germany for his colleagues.

"Laserwelt was excited to demonstrate Aura™ at this major dermatology conference," said Michael Landsberg, Owner and President of Laserwelt, one of the most successful independent distributors of medical devices in German-speaking countries. "The device was very well received, and we anticipate a successful ongoing launch of Aura™ in Germany as awareness and adoption of this innovative skin cancer detector continues to grow."

The European medical device market is the second largest in the world, worth over $78 billion and representing 30 per cent of the world market - second only to the United States. Last year, Aura™ received the Conformite Europeenne (CE) Mark approval. CE Mark is recognized by all the 27 Member States of the EU, including Germany, which has a total population of over 81 million people, and over 5,000 dermatologists serving the country.

"Germany is one of the largest markets in Europe for dermatological and skin care devices," said Thomas Braun, President & CEO of Verisante. "With skin cancer on the rise in Germany, there is an enormous need for an objective tool that can assist dermatologists in providing an immediate and accurate diagnosis. We are confident that based on the Aura's™ clinical study results, the device will provide significant benefits to dermatologists and patients in Germany, Austria and Liechtenstein."

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.




Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information